Le produit candidat GI-5005 sur le VHC de GlobeImmune améliore la réponse virologique prolongée de 10 pour cent, s'avérant être le premier vaccin thérapeutique susceptible de s'attaquer au VHC
15 avr. 2010 13h00 HE
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) -
GlobeImmune, Inc. a annoncé aujourd'hui les données de la phase finale 2b
du GI-5005, le produit candidat Tarmogen(r) expérimental de...
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
17 mars 2010 16h12 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 17, 2010) - GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted...
GlobeImmune Announces $17.5 Million Series E Financing
19 janv. 2010 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel
therapies for patients with cancer and infectious diseases, today announced
a Series E Preferred Stock...
GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15%
02 nov. 2009 08h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 2, 2009) - GlobeImmune Inc. will present Phase 2b data
today at the 60th Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD)...
GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting
06 oct. 2009 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - October 6, 2009) - GlobeImmune Inc. today announced that a late
breaking abstract related to GI-5005, its investigational hepatitis C virus
(HCV) product candidate, has...
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
15 mai 2009 07h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO and SUMMIT, NJ--(Marketwire - May 15, 2009) - GlobeImmune, Inc. and Celgene
Corporation (NASDAQ: CELG) today announced a worldwide strategic
collaboration focused on the discovery,...
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 Percent in Phase 2 Clinical Trial
24 avr. 2009 01h59 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 24, 2009) - Twelve-week Phase 2 clinical trial data show
that patients treated with GI-5005, GlobeImmune's targeted molecular
immunogen (Tarmogen®) for the...
GlobeImmune Initiates Phase 1 Clinical Trial With NCI in CEA Over-Expressing Cancers
16 avr. 2009 08h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 16, 2009) - GlobeImmune, Inc. today announced the
initiation of a Phase 1 clinical trial to investigate the safety and
tolerability of a new Tarmogen, GI-6207, in...
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
01 nov. 2008 11h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 1, 2008) - Four-week Phase 2 clinical trial data show
that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular
immunogen (Tarmogen®), doubled...
GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to Be Highlighted at the AASLD President's Press Conference
28 oct. 2008 08h00 HE
|
GlobeImmune Inc.
LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that
four-week data from the on-going Phase 2 clinical trial for GI-5005, the
Company's therapeutic vaccine...